Evolocumab

Comercialización: Repatha: Europa (EMA), EE.UU. (FDA)

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)

Estado: Completado

Subanálisis Fourier

ICP previa Territorios vasculares Revascularización compleja / bypass coronario Síndrome metabólico IM reciente Estenosis aórtica Según IM subsiguiente Ictus ERC Eventos CV totales Lp(a) Cálculo del LDL Gravedad y extensión de enfermedad coronaria Inflamación EAP Diabetes Niveles muy bajos de LDL

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension (FOURIER OLE)

Estado: Completado

Clinical Trials

Imaging of Coronary Plaques in Participants Treated With Evolocumab

Estado: Completado

Clinical Trials Pubmed 1

Global Assessment of Plaque regression With a PCSK9 antibody as Measured by intravascular Ultrasound (GLAGOV)

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2

Evolocumab in Acute Coronary Syndrome (EVACS)

Estado: Activo, no reclutando

Clinical Trials Pubmed 1

Evolocumab in Patients With Acute MI (EVACS II)

Estado: Reclutando

Clinical Trials

Evolocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

Estado: Completado

Clinical Trials Pubmed 1

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

Estado: Activo, no reclutando

Clinical Trials

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Estado: Completado

Clinical Trials Pubmed 1

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Estado: Completado

Clinical Trials

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (TESLA)

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2

Durable Effect of PCSK9 Antibody Compared with Placebo Study (DESCARTES)

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2 Pubmed 3

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Estado: Completado

Clinical Trials Pubmed 1

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG)

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2

Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders (HAUSER-RCT)

Estado: Completado

Clinical Trials Pubmed 1

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody (FLOREY)

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2 Pubmed 3 Pubmed 4

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 (RUTHERFORD-2)

Estado: Completado

Clinical Trials Pubmed 1

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia (OSLER-2)

Estado: Completado

Clinical Trials Pubmed 1

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-2 (GAUSS-2)

Estado: Completado

Clinical Trials Pubmed 1

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

Estado: Completado

Clinical Trials Pubmed 1

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)

Estado: Completado

Clinical Trials Pubmed 1

LDL-C Assessment with PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Estado: Completado

Clinical Trials Pubmed 1

Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH). (HAUSER-OLE)

Estado: Completado

Clinical Trials

Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (BANTING)

Estado: Completado

Clinical Trials Pubmed 1

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)) (ANITSCHKOW)

Estado: Completado

Clinical Trials Pubmed 1

A Double-blind, Randomized Study in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia (BERSON)

Estado: Completado

Clinical Trials Pubmed 1

Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI (AMUNDSEN)

Estado: Reclutando

Clinical Trials

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Estado: No reclutando

Clinical Trials

A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy (SLICE-CEA)

Estado: Reclutando

Clinical Trials

Lipid Management in Renal Transplant Recipients Using Evolocumab

Estado: Reclutando

Clinical Trials